Skip to main content Accessibility help
×
Home

Correlation between liver cirrhosis and risk of death from oral cancer: Taiwan cohort study

  • K-P Chang (a1) (a2) (a3), C-C Lee (a1) (a2) (a3), Y-C Su (a4), M-L Han (a5), T-H Kung (a5) and H-J Chang (a6)...

Abstract

Background:

A nationwide population-based cohort was used to examine the severity of liver cirrhosis and risk of mortality from oral cancer.

Methods:

The cohort consisted of 3583 patients with oral cancer treated by surgery between 2008 and 2011 in Taiwan. They were grouped on the basis of normal liver function (n = 3471), cirrhosis without decompensation (n = 72) and cirrhosis with decompensation (n = 40). The primary endpoint was mortality. Hazard ratios of death were also determined.

Results:

The mortality rates in the respective groups were 14.8 per cent, 20.8 per cent and 37.5 per cent at one year (p < 0.001). The adjusted hazard ratios of death at one year for each group compared to the normal group were 2.01 (p = 0.021) for cirrhotic patients without decompensation, 4.84 (p < 0.001) for those with decompensation and 2.65 (p < 0.001) for those receiving chemotherapy.

Conclusion:

Liver cirrhosis can be used to predict one-year mortality in oral cancer patients. Chemotherapy should be used with caution and underlying co-morbidities should be managed in cirrhotic patients to reduce mortality risk.

Copyright

Corresponding author

Address for correspondence: Dr Heng-Jui Chang, Department of Radiation Oncology, Min-Sheng General Hospital, Taoyuan, Taiwan No. 168, Jingguo Rd, Taoyuan Dist, Taoyuan City 330, Taiwan E-mail: bryancgu@yahoo.com.tw

References

Hide All
1 Health Promotion Administration Ministry of Health and Welfare, Taiwan. Cancer Registry Annual Report 2011, Taiwan; February 2014. In: http://www.hpa.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=201404160001 [10 April 2015]
2 Perkins, TM, Perkins, I. Chronic alcoholism: a common risk factor in oral cancer and alcoholic cirrhosis. Compend Contin Educ Dent 2001;22:4951
3 Friedman, LS. The risk of surgery in patients with liver disease. Hepatology 1999;29:1617–23
4 O'Leary, JG, Yachimski, PS, Friedman, LS. Surgery in the patient with liver disease. Clin Liver Dis 2009;13:211–31
5 Friedman, LS. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc 2010;121:192205
6 Farnsworth, N, Fagan, SP, Berger, DH, Awad, SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004;188:580–3
7 Suman, A, Barnes, DS, Zein, NN, Levinthal, GN, Connor, JT, Carey, WD. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004;2:719–23
8 Neeff, H, Mariaskin, D, Spangenberg, HC, Hopt, UT, Makowiec, F. Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores. J Gastrointest Surg 2011;15:111
9 Hanje, AJ, Patel, T. Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;4:266–76
10 Klemperer, JD, Ko, W, Krieger, KH, Connolly, M, Rosengart, TK, Altorki, NK et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 1998;65:85–7
11 Filsoufi, F, Salzberg, SP, Rahmanian, PB, Schiano, TD, Elsiesy, H, Squire, A et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 2007;13:990–5
12 Shaheen, AA, Kaplan, GG, Hubbard, JN, Myers, RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. Liver Int 2009;29:1141–51
13 Liao, JC, Chen, WJ, Chen, LH, Niu, CC, Fu, TS, Lai, PL et al. Complications associated with instrumented lumbar surgery in patients with liver cirrhosis: a matched cohort analysis. Spine J 2013;13:908–13
14 Wu, CC, Yeh, DC, Lin, MC, Liu, TJ, P'Eng, FK. Improving operative safety for cirrhotic liver resection. Br J Surg 2001;88:210–15
15 Schroeder, RA, Marroquin, CE, Bute, BP, Khuri, S, Henderson, WG, Kuo, PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006;243:373–9
16 Clavien, PA, Petrowsky, H, DeOliveira, ML, Graf, R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545–59
17 Demetriades, D, Constantinou, C, Salim, A, Velmahos, G, Rhee, P, Chan, L. Liver cirrhosis in patients undergoing laparotomy for trauma: effect on outcomes. J Am Coll Surg 2004;199:538–42
18 Lekholm, U, Stenman, G. Induction of oral cancer by 7,12-dimethylbenz[a]anthracene in rats with liver cirrhosis. Acta Odontol Scand 1989;47:265–9
19 Randi, G, Altieri, A, Gallus, S, Franceschi, S, Negri, E, Talamini, R et al. History of cirrhosis and risk of digestive tract neoplasms. Ann Oncol 2005;16:1551–5
20 Kao, HK, Chang, KP, Ching, WC, Tsao, CK, Cheng, MH, Wei, FC. The impacts of liver cirrhosis on head and neck cancer patients undergoing microsurgical free tissue transfer: an evaluation of flap outcome and flap-related complications. Oral Oncol 2009;45:1058–62
21 Chang, PH, Yeh, KY, Huang, JS. Competing causes of death in patients with oral cavity cancer in a single cancer center in Taiwan. J Cancer Res Pract 2013;29:1421
22 Chang, TS, Chang, CM, Hsu, TW, Lin, YS, Lai, NS, Su, YC et al. The combined effect of individual and neighborhood socioeconomic status on nasopharyngeal cancer survival. PLoS One 2013;8:e73889
23 Su, FH, Chang, SN, Chen, PC, Sung, FC, Huang, SF, Chiou, HY et al. Positive association between hepatitis C infection and oral cavity cancer: a nationwide population-based cohort study in Taiwan. PLoS One 2012;7:e48109
24 Goldacre, MJ, Wotton, CJ, Yeates, D, Seagroatt, V, Collier, J. Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J Gastroenterol Hepatol 2008;20:384–92
25 Perz, JF, Armstrong, GL, Farrington, LA, Hutin, YJ, Bell, BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–38
26 Sung, JL, Chen, DS. Hepatitis B antigen and antibody in liver disease in Taiwan. In: Lee, SK, ed. Proceedings of the 5th Asian Pacific Congress of Gastroenterology, 23–27 May, 1976, Singapore. Singapore: Asian Pacific Congress of Gastroenterology, 1976;265–9
27 Poschl, G, Seitz, HK. Alcohol and cancer. Alcohol Alcohol 2004;39:155–65
28 Jepsen, P, Vilstrup, H, Andersen, PK, Lash, TL, Sorensen, HT. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology 2008;48:214–20
29 Chang, TT, Gish, RG, Man, RD, Gadano, A, Sollano, J, Chao, YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001–10
30 Lai, CL, Shouval, D, Lok, AS, Chang, TT, Cheinquer, H, Goodman, Z et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–20
31 Köklü, S, Tuna, Y, Gülşen, MT, Demir, M, Aydin, SK, Muhammet, CK et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:8894
32 Ao, ZH, Xu, ZH, Lu, ZM, Xu, HY, Zhang, XM, Dou, WF et al. Niuchangchih (Antrodia camphorata) and its potential in treating liver diseases. J Ethnopharmacol 2009;121:194212
33 Hseu, YC, Chang, WC, Hseu, YT, Lee, CY, Yech, YJ, Chen, PC et al. Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci 2002;71:469–82
34 Lin, WC, Kuo, SC, Lin, WL, Fang, HL, Wang, BC. Filtrate of fermented mycelia from Antrodia camphorata reduces liver fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2006;12:2369–74
35 Shu, CH, Lung, MY. Effect of pH on the production and molecular weight distribution of exopolysaccharide by Antrodia camphorata in batch cultures. Process Biochem 2004;39:931–7
36 Haddad, Y, Vallerand, D, Brault, A, Haddad, PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2011;2011:nep164
37 Al-Anati, L, Essid, E, Reinehr, R, Petzinger, E. Silibinin protects OTA-mediated TNF-a release from perfused rat livers and isolated rat Kupffer cells. Mol Nutr Food Res 2009;53:460–6
38 Kostek, H, Szponar, J, Tchórz, M, Majewska, M, Lewandowska-Stanek, H. Silibinin and its hepatoprotective action from the perspective of a toxicologist [in Polish]. Przegl Lek 2012;69:541–3

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed